文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-SiFAlin-TATE PET首个人体研究:新型18F标记生长抑素类似物用于神经内分泌肿瘤显像

Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2019-09-06

结果显示18F-SiFAlin-TATE在肾脏摄取显著更高,在肝、淋巴结和骨转移灶中肿瘤摄取显著更高,肿瘤/肝和肿瘤/脾比值与68Ga-DOTA-TOC相当,图像质量优良且观察者间一致性高。

要点

  • 18F-SiFAlin-TATE在肝、淋巴结和骨转移灶的SUVmax显著高于68Ga-DOTA-TOC。
  • 肾脏摄取显著更高,但肿瘤/肝和肿瘤/脾比值与68Ga-DOTA-TOC相当。
  • 图像质量优良,观察者间一致性高,且标记流程类似药盒式操作。

核心结论

  • 18F-SiFAlin-TATE具有良好图像质量、药盒式标记流程和有前景的临床性能,可改善NET PET显像的后勤与诊断可能性。
  • 首次临床结果值得进一步系统研究18F-SiFAlin-TATE在NET患者中的临床应用。

研究设计与样本

  • 比较两种示踪剂在正常器官的生物分布和NET病灶的肿瘤摄取,测量SUVmean和SUVmax。
  • 计算平均和最大肿瘤/肝比值(TLR)及肿瘤/脾比值(TSR)。
  • 由5名盲法读片者对图像质量进行视觉评分,并进行组内相关系数(ICC)分析观察者间一致性。

主要发现

  • 18F-SiFAlin-TATE在肝、脾和肾上腺的摄取略高于68Ga-DOTA-TOC,但差异无统计学意义。
  • 18F-SiFAlin-TATE在肾脏的摄取显著高于68Ga-DOTA-TOC。
  • 18F-SiFAlin-TATE在肝转移灶的SUVmax为18.8 ± 8.4,68Ga-DOTA-TOC为12.8 ± 5.6(p < 0.001)。
  • 18F-SiFAlin-TATE在淋巴结转移灶的SUVmax为23.8 ± 20.7,68Ga-DOTA-TOC为17.4 ± 16.1(p < 0.001)。
  • 18F-SiFAlin-TATE在骨转移灶的SUVmax为16.0 ± 10.1,68Ga-DOTA-TOC为10.3 ± 5.7(p < 0.01)。

关键数值与推荐

  • 肿瘤/肝比值和肿瘤/脾比值与68Ga-DOTA-TOC相当。
  • 图像质量观察者间一致性的ICC分析为显著至几乎完美。
  • 多数病例中68Ga-DOTA-TOC和18F-SiFAlin-TATE PET的图像质量均评为优良。

临床怎么用

  • 18F-SiFAlin-TATE可作为NET PET显像的潜在替代示踪剂,具有更优的后勤优势和良好的诊断性能。
  • 需注意其肾脏摄取显著高于68Ga-DOTA-TOC。
  • 目前仅为首次临床结果,尚需进一步系统研究验证其临床应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: PET/CT using 68Ga-labeled somatostatin analogs (SSA) targeting somatostatin receptors (SSR) on the cell surface of well-differentiated neuroendocrine tumors (NET) represents the clinical reference standard for imaging. However, economic and logistic challenges of the 68Ge/68Ga generator-based approach have disadvantages over 18F-labeled compounds. Here, we present the first in-human data of 18F-SiFAlin-TATE, a novel 18F-labeled, SSR-targeting peptide. The aim was to compare the intra-individual biodistribution, tumor uptake, and image quality of 18F-SiFAlin-TATE to the clinical reference standard 68Ga-DOTA-TOC. METHODS: Thirteen patients with NET staged with both 68Ga-DOTA-TOC and 18F-SiFAlin-TATE PET/CT have been included in this retrospective analysis. We compared the biodistribution in normal organs and tumor uptake of NET lesions by SUVmean and SUVmax measurement for tracers. Additionally mean and max tumor-to-liver (TLR) and tumor-to-spleen ratios (TSR) have been calculated by division of SUVmean and SUVmax of tumor lesions by the SUVmean of the liver and spleen, respectively. Additionally, image quality was visually rated by 5 blinded readers and an intra-class correlation (ICC) analysis on inter-observer agreement has been performed. RESULTS: Compared with 68Ga-DOTA-TOC, the biodistribution of 18F-SiFAlin-TATE showed somewhat higher, however, statistically not significant higher uptake in the liver, spleen, and adrenal glands. Significantly higher uptake was observed in the kidneys. Tumor uptake was higher in most tumor lesions with significantly higher uptake in common metastatic sites of NET including the liver (SUVmax 18.8 ± 8.4 vs. 12.8 ± 5.6; p < 0.001), lymph nodes (SUVmax 23.8 ± 20.7 vs. 17.4 ± 16.1; p < 0.001) and bone (SUVmax 16.0 ± 10.1 vs. 10.3 ± 5.7; p < 0.01) for 18F-SiFAlin-TATE. The high tumor uptake resulted in favorable TLR and TSR, comparable with that of 68Ga-DOTA-TOC. The ICC analysis on the inter-observer agreement on image quality was substantial and almost perfect. Image quality was rated as excellent in most cases in both 68Ga-DOTA-TOC and 18F-SiFAlin-TATE PET. CONCLUSION: The favorable characteristics of 18F-SiFAlin-TATE with a high image quality, the kit-like labeling procedure, and the promising clinical performance enable improved logistics and diagnostic possibilities for PET imaging of NET. Our first clinical results warrant further systematic studies investigating the clinical use of 18F-SiFAlin-TATE in NET patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Ilhan H, Lindner S, Todica A, et al. Biodistribution and first clinical results of 18F-SiFAlin-TATE PET: a novel 18F-labeled somatostatin analog for imaging of neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2019. PMID: 31492994. doi:10.1007/s00259-019-04501-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。